Patient, physician, pharmacy, and pharmacy benefit design factors related to generic medication use

Journal of General Internal Medicine

Volumn 22, Issue 9, 2007, Pages 1298-1304

  Shrank, William H ^a   Stedman, Margaret ^a   Ettner, Susan L ^d   DeLapp, Dee ^e,f   Dirstine, June ^e,f   Brookhart, M Alan ^a   Fischer, Michael A ^a   Avorn, Jerry ^a   Asch, Steven M ^b,c,d  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b VA GREATER LOS ANGELES HEALTHCARE SYSTEM   (United States)

^c RAND CORPORATION   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e Anthem Blue Cross/Blue Shields CT O   (United States)

^f Anthem Prescription Management   (United States)

Author keywords

Design; Generic medications; Medication costs; Patient; Pharmacy; Pharmacy benefit; Physician

Indexed keywords

GENERIC DRUG;

ARTICLE; CONFIDENCE INTERVAL; COST BENEFIT ANALYSIS; DRUG COST; DRUG INFORMATION; DRUG PREFERENCE; DRUG USE; HEALTH INSURANCE; HUMAN; OBSERVATIONAL STUDY; PATIENT; PHYSICIAN; PRESCRIPTION; PROBABILITY; RISK FACTOR;

ADULT; DRUGS, GENERIC; FEMALE; HUMANS; INSURANCE BENEFITS; MALE; MANAGED CARE PROGRAMS; MIDDLE AGED; PATIENT SATISFACTION; PHARMACY; PHYSICIAN'S ROLE; SOCIOECONOMIC FACTORS;

EID: 34547838425     PISSN: 08848734     EISSN: 15251497     Source Type: Journal    
DOI: 10.1007/s11606-007-0284-3     Document Type: Article

References (33)

1. IMS Health. Available at: http://www.imshealth.com/ims/portal/front/ articleC/0,2777,6599_3665_77180090,00.html. Accessed February 5, 2007.
2. Heffler S, Levit K, Smith et al. Health spending growth up in 1999; faster growth expected in the future. Health Aff. 2001;20(2):193-203.
3. Hoffman JM, Shah ND, Vermeulen LC, Hunkler RJ, Hontz KM. Projecting future drug expenditures-2004. Am J Health Syst Pharm. 2004;61(2):145-58.
4. Fischer MA, Avorn J. Potential savings from increased use of generic drugs in the elderly: what the experience of Medicaid and other insurance programs means for a Medicare drug benefit. Pharmacoepidemiol Drug Saf. 2004;13(4):207-14.
5. Fischer MA, Avorn J. Economic implications of evidence-based prescribing for hypertension: can better care cost less? JAMA. 2004;291(15):1850-6.
6. Kohl H, Shrank WH. Increasing generic drug use in Medicare Part D: The role of government. J Am Geriatr Soc. 2007;55(7):1106-9
7. Haas JS, Phillips KA, Gerstenberger EP, Seger AC. Potential savings from substituting generic drugs for brand-name drugs: medical expenditure panel survey, 1997-2000. Ann Intern Med. 2005;142(11):891-7.
8. Kaiser Family Foundation and Health Research and Educational Trust. Employer health benefits: 2004 summary of findings. (Accessed October 12, 2004, at http://www.kff.org/insurance/7148/loader.cfm?url=/commonspot/security/ getfile.cfm&PageID=46206 )
9. Shrank WH, Hoang T, Ettner SL, et al. The implications of choice: prescribing generic or preferred formulary medications improves adherence to chronic medications. Arch Intern Med. 2006;166:332-7.
10. Federman AD, Halm EA, Siu AL. Use of generic cardiovascular medications by elderly Medicare beneficiaries receiving generalist or cardiologist care. Med Care. 2007;45(2):109-15 (Feb).
11. Federman AD, Halm EA, Zhu C, Hochman T, Siu AL. Association of income and prescription drug coverage with generic medication use among older adults with hypertension. Am J Manag Care. 2006;12(10):611-8 (Oct).
12. Shrank WH, Fox SA, Kirk A, et al. The Effect of Pharmacy Benefit Design on Patient-Physician Communication about Costs. J Gen Intern Med. 2006;21(4):334-9.
13. Shrank WH, Young HN, Ettner SL, Glassman P, Asch SM, Kravitz RL. Do the incentives in 3-tier pharmaceutical benefit plans operate as intended? Results from a physician leadership survey. Am J Manag Care. 2005;11(1):16-22.
14. Alexander GC, Casalino LP, Meltzer DO. Physician strategies to reduce patients' out-of-pocket prescription costs. Arch Intern Med. 2005;165(6):633-6.
15. Oregon Health Sciences University. Drug Evaluation Review Project. Accessed 12/19/05 at: http://www.ohsu.edu/drugeffectiveness/reports/index.htm.
16. Halpern MT, Khan ZM, Schmier JK, et al. Recommendations for evaluating compliance and persistence with hypertension therapy using retrospective data. Hypertension. 2006;47(6):1039-48, Jun.
17. Soobader M, LeClere FB, Hadden W, Maury B. Using aggregate geographic data to proxy individual socioeconomic status: does size matter? Am J Public Health. 2001;91:632-6.
18. Geronimus AT, Bound J. Use of census-based aggregate variables to proxy for socioeconomic group: evidence from national samples. Am J Epidemiol. 1998;148(5):475-86.
19. Performance of comorbidity scores to control for confounding in epidemiologic studies using claims data. Am J Epidemiol. 2001;154(9):854-64 (Nov 1).
20. Baldwin LM, Adamache W, Klabunde CN, Kenward K, Dahlman C, Warren JL. Linking physician characteristics and medicare claims data: issues in data availability, quality, and measurement. Med Care. 2002;40(8 Suppl):IV-82-95.
21. Shea JA, Kletke PR, Wozniak GD, Polsky D, Escarce JJ. Self-reported physician specialties and the primary care content of medical practice: a study of the AMA physician masterfile. American Medical Association. Med Care. 1999;37(4):333-8.
22. Rector TS, Finch MD, Danzon PM, Pauly MV, Manda BS. Effect of tiered prescription copayments on the use of preferred brand medications. Med Care. 2003;41(3):398-406.
23. Huskamp HA, Deverka PA, Epstein AM, Epstein RS, McGuigan KA, Frank RG. The effect of incentive-based formularies on prescription-drug utilization and spending. N Engl J Med. 349(23):2224-32.
24. Schneeweiss S, Walker AM, Glynn RJ, Maclure M, Dormuth C, Soumerai SB. Outcomes of reference pricing for angiotensin-converting-enzyme inhibitors. N Engl J Med. 2002;346(11):822-9.
25. Landsman PB, Yu W, Liu X, Teutsch SM, Berger ML. Impact of 3-tier pharmacy benefit design and increased consumer cost-sharing on drug utilization. Am J Manag Care. 2005;(10):621-8.
26. Goldman DP, Joyce GF, Escarce JJ, et al. Pharmacy benefits and the use of drugs by the chronically ill. JAMA. 2004;291(19):2344-50.
27. Motheral B, Fairman KA. Effect of a three-tier prescription copay on pharmaceutical and other medical utilization. Med Care. 2001;39(12):1293-304.
28. Christian-Herman J, Emons M, George D. Effects of generic-only drug coverage in a Medicare HMO. Health Aff (Millwood). 2004;Suppl Web Exclusives:W4-455-68.
29. Gibson TB, Ozminkowski RJ, Goetzel RZ. The effects of prescription drug cost sharing: a review of the evidence. Am J Manag Care. 2005;11(11):730-40.
30. Shrank WH. The effect of incentive-based formularies on drug utilization and spending. N Engl J Med. 2004;350(10):1057.
31. Gross R, Zhang Y, Grossberg R. Medication refill logistics and refill adherence in HIV. Pharmacoepidemiol Drug Saf. 2005;14(11):789-93.
32. IMS Health. 2004 year end U.S. prescription and sales information and commentary. http://www.imshealth.com/ims/portal/front/articleC/0,2777, 6599_3665_69890098,00.html. Accessed 5/14/07.
33. Adair RF, Holmgren LR. Do drug samples influence resident prescribing behavior? A randomized trial. Am J Med. 2005;118(8):881-4.